Fagron NV logo

Fagron NV (FAGRb)

Market Closed
CBOE CBOE
- Market Cap
18.45 P/E Ratio
1.56% Div Yield
- Volume
0.99 Eps
Want to track FAGRb and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

FAGRb is not paying dividends to its shareholders.
The last earnings report, released on Apr 09, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
Fagron NV has completed 1 stock splits, with the recent split occurring on Jun 17, 2016.
The company's stock is traded on 7 different exchanges and in various currencies, with the primary listing on XBRU (EUR).

Fagron NV (FAGRb) FAQ

On which exchange is it traded?

Fagron NV is listed on CBOE.

What is its stock symbol?

The ticker symbol is FAGRb.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 1.56%.

What is its market cap?

As of today, no market cap data is available.

Has Fagron NV ever had a stock split?

Fagron NV had 1 splits and the recent split was on Jun 17, 2016.

Fagron NV Profile

Specialty Retail Industry
Consumer Discretionary Sector
Mr. Rafael Padilla CEO
CBOE Exchange
BE0003874915 ISIN
BE Country
4,193 Employees
- Last Dividend
17 Jun 2016 Last Split
- IPO Date

Overview

Fagron NV is a globally operating pharmaceutical compounding company, dedicated to offering personalized pharmaceutical care to a broad range of healthcare facilities and patients. The company categorizes its operations into three main segments: Essentials, Brands, and Compounding Services. It is actively engaged in the innovation of concepts, vehicles, and formulations to advance pharmaceutical compounding. Founded in 1990 and originally known as Arseus NV, the company underwent a name change to Fagron NV in January 2015 and has since established its base in Nazareth, Belgium. Fagron's mission is to bridge the gap between the unique needs of patients and the capabilities of the pharmaceutical industry by providing custom solutions. To support this mission, it also runs the Fagron Academy, which offers education and training to pharmacists and prescribers.

Products and Services

  • DiluCap: These are a range of excipients designed to assist in the compounding of capsule formulations, catering to a variety of pharmaceutical needs.
  • Imuno TF Complex: This product aids in the regulation of immune responses, offering support in immune system regulation.
  • Pigmerise: Targeted at those suffering from hypopigmentation disorders, Pigmerise utilizes a natural phytocomplex to address these conditions.
  • Pentravan: A cream base designed to enhance the delivery of medications by avoiding first-pass metabolism and preventing gastrointestinal erosion, thus ensuring effective therapy.
  • Nourisil MD: Recommended as a first line therapy, this product aids in the prevention and treatment of scars and keloids, offering both curative and preventive benefits for skin health.
  • Neogen: This line of hair care products addresses various needs and conditions, including hair loss, with a focus on promoting hair health and growth.
  • TrichoConcept: Specifically formulated for the treatment of alopecia, this range offers targeted solutions for those experiencing hair loss.
  • Fagron Advanced Derma: Focused on skincare, this portfolio covers basic skin care needs, compound pharmaceutical treatment options, and personalized dermatological care, catering to individual requirements.
  • SyrSpend SF: This range ensures pharmaceutical stability, consistency in dosage, and patient comfort, improving the overall medication administration experience.

Contact Information

Address: Venecoweg 20A, Nazareth, Belgium, 9810
Phone: 32 800 128 80